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Alzheimer’s disease (AD) is a protein conformational disorder characterized by two major
neuropathological features: extracellular accumulations of amyloid-β peptides in the form of
plaques and intracellular tangles, consisting of hyperphosphorylated tau proteins. Several
morphological and functional changes are associated with these lesions in the diseased
brain, such as dendritic and synaptic alterations, as well as microglial and astroglial recruit-
ment and their activation. The availability of transgenic mouse models that mimic key
aspects of the disease in conjunction with recent advances in two-photon imaging facil-
itate the study of fundamental aspects of AD pathogenesis and allow for longitudinally
monitoring the efﬁcacy of therapeutic interventions. Here, we review the ambitious efforts
to understand the relationship between the main neuropathological hallmarks of AD and
their associated structural and functional abnormalities by means of in vivo two-photon
imaging.
Keywords: amyloid plaques, neurofibrillary tangles, dendritic spines, glial cells, multiphoton imaging, microglia,
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INTRODUCTION
Longevity is a long-cherished dream of mankind, but the down-
side of an aging population is currently one of the big challenges
society is facing. Alzheimer’s disease (AD), as the most common
form of dementia in the elderly, currently affects ∼35 million
people worldwide (Prince et al., 2011). It is a fatal, progressive,
neurodegenerative disease characterized by memory impairment
and cognitive decline. When Alois Alzheimer ﬁrst described the
disease in 1906/07 (Alzheimer, 1907), he had already identiﬁed
the pathological hallmarks that still, to this day, constitute the
major diagnostic criteria for AD (Jack et al., 2011). The most
prominent of which are senile plaques, representing extracellu-
lar proteinaceous aggregates that mainly consist of the amyloid-β
peptide (Aβ; Glenner and Wong, 1984; Masters et al., 1985). Aβ
is derived from the sequential cleavage of the amyloid-β precur-
sor protein (APP) by the β- and γ-secretases (Haass, 2004; Haass
and Selkoe, 2007; Lichtenthaler et al., 2011). Neuroﬁbrillary tan-
gles (NFT) constitute the second major hallmark of AD (Kosik
et al., 1986; Nukina and Ihara, 1986). These intracellular aggre-
gates of the hyperphosphorylated microtubule-associated protein
tau form intrasomal inclusions as well as neuropil threads, and
are thought to be causally related to neuronal apoptosis (Dickson,
2004; Spires-Jones et al., 2009b; Wakasaya et al., 2011).
Interestingly, although plaques and tangles pathologically
deﬁne the disease, it is the loss of synapses that correlates strongly
with the dementia typical of AD (Masliah et al., 1991; Terry
et al., 1991; Scheff et al., 2006). Research over the past decade
has thus focused on the mechanisms causing synaptic deteriora-
tion, including the abnormal accumulation of Aβ and tau. The
resulting decrease of synapse density is believed to eventually lead
to neuronal network disruption and cognitive decline.
Traditional histological analyses of affected brains only allow
for a static assessment of pathology. The advent of two-photon
microscopy (Denk et al., 1990) has enabled in vivo long-term
imaging studies (Holtmaat et al., 2009), from which the ﬁeld of
AD research has beneﬁted tremendously. In vivo imaging of trans-
genic mice through a cranial window not only allows to monitor
general neuropathological features of AD-like lesions (Table 1;
Figure 1), but also to address questions regarding the kinetics and
temporal sequence of events (Figure 2; Bacskai et al., 2001; Spires
et al., 2005; Spires-Jones et al., 2011). Two-photon microscopy
furthermore facilitates direct observation of the effects of new
treatment approaches. Although none of the mouse models avail-
able to date perfectly recapitulates the human AD neuropathology
in its entirety, they still represent a valuable tool to precisely study
key aspects of the disease, such as the occurrence and growth
of amyloid plaques, the onset and progression of dendritic spine
pathology, or the induction of neuronal apoptosis (Radde et al.,
2008).
We here review some of the key ﬁndings and concepts that have
emerged from the rapidly growing body of literature, on structural
and functional alterations in transgenic mouse models of AD as
revealed by in vivo two-photon microscopy.
STRUCTURAL IN VIVO IMAGING
IMAGING AMYLOID DEPOSITS IN APP TRANSGENIC MICE
Amyloid-β plaques have been studied extensively as one of the
major hallmarks of AD, and as a consequence many treatment
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Table 1 | Structures analyzed in mouse models of Alzheimer’s disease by in vivo two-photon microscopy.
Structure analyzed Transgenic mouse model Dyes Reference
Amyloid-β plaques APPswe/PS1dE9,
APPswe/PS1L166P, PDAPP, Tg2576
Thioﬂavin S,
Methoxy-X04
Christie et al. (2001b), Bolmont et al. (2008), Meyer-Luehmann et al.
(2008),Yan et al. (2009), Burgold et al. (2011), Hefendehl et al. (2011)
Cerebral amyloid angiopathy APPswe/PS1dE9, PDAPP, Tg2576 Thioﬂavin S,
Methoxy-X04
Garcia-Alloza et al. (2006b), Robbins et al. (2006), Prada et al. (2007)
Neuroﬁbrillary tangles rTg4510 Thioﬂavin S Spires-Jones et al. (2008), de Calignon et al. (2009), de Calignon
et al. (2010)
Neurite structures (dendritic
spines, dystrophic neurites,
neurite curvature)
GFP-M,YFP-H – Tsai et al. (2004), Spires et al. (2005), Grutzendler et al. (2007),
Spires-Jones et al. (2007), Meyer-Luehmann et al. (2008), Bittner
et al. (2010), Jung et al. (2011)
Microglia CX3CR1-GFP, Iba1-GFP – Bolmont et al. (2008), Koenigsknecht-Talboo et al. (2008), Meyer-
Luehmann et al. (2008), Fuhrmann et al. (2010), Liu et al. (2010)
FIGURE 1 | Structures imaged in APP transgenic mice in vivo. (A)
Maximum projection of a z-stack with GFP expressing neuronal structures
pseudocolored in green and Methoxy-XO4 labeled amyloid plaques shown
in blue (indicated by red arrowhead). Neurite curvature (depicted by white
lines) corresponds to the ratio of the length of the curved neuritic stretch to
the straight end-to-end length of the same stretch (here R =1.08). (B)
Dystrophic neurites (marked with asterisks) in the close vicinity of a plaque
(red arrowhead). (C) Activated microglia (CX3CR1-GFP+/−; denoted by
asterisks) encompassing a plaque (red arrowheads) next to a blood vessel
stained with Texas red. (D) Neuroﬁbrillary tangles labeled with Thioﬂavin S
(white arrows). Scale bars represent 30μm (A), 20μm (B,C), and 15μm
(D), respectively.
studies are aimed at reducing the formation of plaques (Shah
et al., 2008; Chopra et al., 2011; Kurz and Perneczky, 2011).
Extracellular amyloid plaques mainly consist of aggregated Aβ
peptides that are derived from a larger APP. To release Aβ,
APP is ﬁrst cleaved at its ectodomain by β-secretase, and sub-
sequently is cleaved intramembranously by γ-secretase (Haass,
2004; Steiner, 2004; Lichtenthaler et al., 2011). Depending on the
exact cleavage site, the released Aβ peptide can vary in length,
with longer Aβ peptides being more prone to aggregation (Yan
and Wang, 2006). According to in vitro models, Aβ aggregation
follows a nucleation polymerization model, where Aβ monomers
form higher molecular-weight oligomers and protoﬁbrils, before
they ﬁnally aggregate into insoluble amyloid plaques (Harper and
Lansbury, 1997).
In order to monitor amyloid plaques in vivo, dyes binding
to beta-pleated sheet protein structures, such as Thioﬂavin S or
Methoxy-XO4, are applied either topically or peripherally,with the
latter agent being able to cross the blood-brain-barrier (Christie
et al., 2001b; Klunk et al., 2002; Bacskai et al., 2003). As opposed to
dyes binding to beta-pleated sheet protein structures, which only
allow for the visualization of the compact forms of plaques, ﬂuo-
rescently labeled antibodies against Aβ additionally mark diffuse
plaques.
Crucial aspects addressed by longitudinal two-photon imaging
are the process of de novo plaque formation aswell as the kinetics of
cerebral amyloidosis. The appearance of new plaques is a rare, but
rapid event that is age-dependent (Meyer-Luehmann et al., 2008;
Burgold et al., 2011; Hefendehl et al., 2011; Figures 2A,B). Previ-
ous studies assessing the kinetics of plaque growth have yielded
somewhat inconsistent ﬁndings. Whereas some studies reported
no signiﬁcant change in plaque size when imaged over the course
of 14 days (Meyer-Luehmann et al., 2008) and up to 150 days
(Christie et al., 2001b), others found an increase in plaque size
only for small plaques (<10μm radius) over the course of 4 weeks
(Bolmont et al., 2008). More recent studies observed growth for all
plaques analyzed, and reported on either growth rates independent
of plaque size (Hefendehl et al., 2011) or a higher growth rate for
newly deposited (i.e., small) compared to pre-existing plaques (Yan
et al., 2009; Burgold et al., 2011). Factors potentially contributing
to these inconsistencies could be of biological or methodological
nature. Among others, the type of the transgenic mouse model
as well as sex and age of the animals differed between the studies
(Table 2). Furthermore, the dye applied in order to label amy-
loid plaques, Methoxy-XO4, is in itself known to interfere with
the process of plaque deposition (Cohen et al., 2009). Therefore
the imaging frequency, i.e., the frequency of dye re-application, is
likely to contribute to the variability in observed plaque growth
(Burgold et al., 2011).
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FIGURE 2 |Time-lapse imaging of structural alterations. (A,B)
Maximum projections of z-stacks with GFP expressing neuronal structures
and Methoxy-XO4 labeled amyloid plaques. Over the course of 1week two
new plaques emerged within the region analyzed (marked with red arrows).
(C,D) (White arrow). (E,F) Spine dynamics of an apical dendritic tuft (layer V
pyramidal neuron of GFP-M mouse). Spines present at both imaging time
points are indicated by white arrowheads, spines lost over the course of
1week are labeled with red arrowheads, spines newly formed during the
same period are marked with yellow arrowheads. Scale bars represent
25μm (B), 10μm (D), and 2μm (F), respectively.
It has also been suggested that the type of cranial window,
used to perform in vivo imaging, might be an additional con-
founding variable. Yan et al. (2009) compared thinned – vs. open
skull preparations and only detected signiﬁcant plaque growth
with the thinned skull preparation. Two recent studies, however,
observed clear plaque growthwith the open skull preparation, sug-
gesting the equivalence of both approaches (Burgold et al., 2011;
Hefendehl et al., 2011). Furthermore it should be mentioned that
image processing and the applied detection stringency, i.e., the
set detection threshold, can also affect the results. Notably, plaque
pathology reaches a ceiling phase, lacking apparent growth, and de
novo plaque formation (Burgold et al., 2011). In summary, longi-
tudinal in vivo two-photon imaging revealed the rapid appearance
and slow, but steady growth of plaques with varying growth rates
inﬂuenced by such factors, as the transgenic mouse models, age
of the animals, initial size of plaques (pre-existing vs. newborn
plaques), or type of cranial window. These studies shed light on
the kinetics of plaque pathology progression, thereby providing
basic knowledge for further therapeutic intervention studies.
In addition to amyloid plaques, extracellular Aβ deposits often
occur within the walls of cerebral and leptomeningeal blood ves-
sels, called cerebral amyloid angiopathy (CAA). CAA results in
a loss of vascular smooth muscle cells and induces microhem-
orrhages (Van Dorpe et al., 2000; Christie et al., 2001a; Winkler
et al., 2001; Fryer et al., 2003). Many of the APP transgenic mouse
models develop not only Aβ deposits in the parenchyma but also
CAA (Calhoun et al., 1999; Van Dorpe et al., 2000; Christie et al.,
2001a; Robbins et al., 2006). However, some APP transgenic mice,
e.g., APPswe/PS1dE9, are not an ideal model to study CAA, as these
mice develop CAA at a much slower rate when compared to other
APPswe transgenic mice (Garcia-Alloza et al., 2006b).
The temporal progression of CAA was ﬁrst approximated by
imaging postmortem intact whole brains of transgenicmice of dif-
ferent ages, revealing a consistent, and stereotyped age-dependent
spatial distribution of CAA (Domnitz et al., 2005). A far more
precise approach to analyze the kinetics of CAA progression is
longitudinal two-photon imaging of the same individual vessel
segment. Thus in vivo imaging of APP transgenic mice at weekly
intervals, starting at the age of 8–11months, showed that the
emergence of CAA is a multifocal event in form of band-like
Aβ deposits (Robbins et al., 2006). Furthermore, in contrast to
the accumulation of amyloid plaques in the parenchyma, CAA
progression tends to propagate from already existing deposits
(Robbins et al., 2006). Therapeutic interventions, such as pas-
sive immunization, was able to halt CAA progression and even
to reduce vascular amyloid in APP transgenic mice, as demon-
strated by immunohistochemical analysis (Schroeter et al., 2008;
Cattepoel et al., 2011). While chronic antibody treatment over
14 days monitored by two-photon microscopy resulted in a robust
CAA regression, a single antibody exposure only led to moder-
ate CAA regression, thus corroborating histological studies (Prada
et al., 2007).
IMAGING NEURITES IN THE VICINITY OF AMYLOID PLAQUES
Albeit pathologically deﬁning the disease and being a diagnostic
criterion, the occurrence of amyloid plaques only poorly corre-
lates with the cognitive decline characteristic of AD (Terry et al.,
1991; Guillozet et al., 2003). A much better correlate is the loss
of synapses (Terry et al., 1991; Masliah et al., 1994). Amyloid
plaques are associated with numerous structural and functional
pathological features, such as neurite curvature (D’Amore et al.,
2003; Garcia-Alloza et al., 2006a; Meyer-Luehmann et al., 2008;
Figure 1A) and breakage (Tsai et al., 2004; Figures 2C,D), neuritic
dystrophies (D’Amore et al., 2003; Tsai et al., 2004; Figure 1B),
synapse loss (Tsai et al., 2004; Spires et al., 2005), accumula-
tion of glial cells (Bolmont et al., 2008; Figure 1C), and altered
neuronal response properties (Busche et al., 2008). Conventional
immunohistochemical techniques have been extensively used to
elucidate the spatial relationship between amyloid plaques and
synaptic markers and found a decrease in synaptic density, both
in AD patients and in transgenic animal models, with synapse
loss being most pronounced in the immediate vicinity of amyloid
plaques (DeKosky et al., 1996; Grutzendler et al., 2007; Knobloch
and Mansuy, 2008; Penzes et al., 2011). These studies however
do not allow for a detailed analysis of the dynamics of synaptic
changes (reviewed by Giannakopoulos et al., 2009).
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Table 2 | Studies analyzing amyloid plaque formation and growth in vivo.
Reference Transgenic
mouse
model
Sex, age at
first imaging
session
Observation
period
Dye Type of
cranial
window
Main finding
Christie et al.
(2001b)
Tg2576 , 18.6months 2–150 days Thioﬂavin S
(0.005% in ACSF)
Thinned
skull
Plaque growth arrest, plaque size
unchanged
Meyer-Luehmann
et al. (2008)
APPswe/
PS1dE9xYFP
, , 5–6months 14 days Methoxy-XO4
(5mg/kg)
Open skull Rapid plaque formation (within 24 h),
stable plaque size up to 2weeks
Tg2576 , , 11months 14 days Rapid plaque formation within 1week
PDAPPxCX3CR1-
GFP
, , 18months 3 days Rapid plaque formation within 24 h
Bolmont et al.
(2008)
APPswe/
PS1L166P x
Iba1-GFP
, , 3–4months 1month Methoxy-XO4
(10mg/kg)
Open skull Stable plaque volume, difference
between size categories: small plaques
(radius<10μm) grew (by 84%), large
plaques (radius>15μm) slightly shrank
(by 12%)
Yan et al. (2009) APPswe/
PS1dE9
, , 6 and
10months
7, 28, 90 days Methoxy-XO4
(5mg/ml)
Thinned
skull
6months: plaque growth (growth rate:
small> large plaques); 10months: no
plaque growth
Open skull 6months: no plaque growth
Burgold et al.
(2011)
Tg2576xYFP , , 12 and
18months
6weeks Methoxy-XO4
(loading dose
2.0mg/kg,
maintenance
dose 0.4mg/kg)
Open skull 12months: growth rate inversely pro-
portional to volume; 18months: lack of
de novo plaque formation and plaque
growth
Hefendehl et al.
(2011)
APPswe/
PS1L166P x
Iba1-GFP
, , 3–4months 6months Methoxy-XO4
(∼5mg/kg)
Open skull Peak of de novo plaque formation at
4–5months, similar growth rates for
newly formed and pre-existing plaques
In vivo two-photon microscopy has therefore been employed
to unravel the temporal sequence of pathological events as well as
their dynamics. To this end, mouse models of AD were crossbred
with mice expressing variants of GFP in neuronal subsets, such
as the GFP-M or YFP-H line (Feng et al., 2000; Tsai et al., 2004;
Meyer-Luehmann et al., 2008). Fluorophore expression in these
mice is regulated by the Thy-1 promoter, which in the cerebral
cortex results in a sparse labeling of mainly layer V neurons (Feng
et al., 2000). Alternatively, neuronal structures can be labeled by
the injection of viral constructs, inducing ﬂuorophore expression
(Spires et al., 2005).
Since Aβ is known to bind to molecular components of the
postsynapse (NMDA-, EphB receptors; Lacor et al., 2007; Cisse
et al., 2011), imaging studies primarily focused on the analysis
of dendritic spines, which are the main site of excitatory synaptic
input to cortical pyramidal cells (Tsai et al., 2004; Spires et al., 2005;
Spires-Jones et al., 2007). Typically, the distal tufts of apical den-
drites of layerV pyramidal neurons are repeatedly imaged. Despite
being relatively stable in adulthood when compared to develop-
ment, dendritic spines are generally ﬂexible and motile structures,
thereby allowing for continuous remodeling of neuronal circuits
(Majewska et al., 2006; Bhatt et al., 2009). Even under baseline con-
ditions (i.e., without any particular sensory deprivation paradigm,
often employed to study synaptic plasticity) a certain fraction of
spines is constantly added and removed,while overall spine density
remains mostly unaffected (Trachtenberg et al., 2002; Holtmaat
et al., 2005, 2009; see however Hofer et al., 2009).
In APPswe/PS1M146L mice, Tsai et al. (2004) found an ongoing
enhanced spine formation and elimination within the peri-plaque
region (i.e., within 15 μm of the plaque border) when imaging
over the course of 2 days for up to 5 weeks. In an APP trans-
genic mouse model (Tg2576) only older animals (18–24months)
showed increased spine elimination and decreased formation
compared to age-matched wildtype control animals (Spires-Jones
et al., 2007). Spine elimination rate exceeded the formation rate,
measured over the relatively short time of 1 h, thereby presumably
resulting in the described spine loss (Spires-Jones et al., 2007). A
recent longitudinal imaging study (Bittner et al., 2010) for the ﬁrst
time analyzed spine changes in a triple transgenic mouse model of
AD (3xTg-AD), bearing in addition to the APPswe and PS1M146V,
also the tauP301L mutation (Oddo et al., 2003). Amyloid plaque-
dependent as well as – independent events were found to underlie
dendritic spine loss (Bittner et al., 2010). Bittner et al. found that
spine loss in hippocampus and frontal cortex only became appar-
ent after plaques were deposited, and was most pronounced in
the vicinity of plaques as observed by immunohistochemistry. In
contrast, somatosensory cortex in the 3xTg-AD mouse model is
devoid of amyloid plaques even in old mice. Longitudinal in vivo
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two-photon imaging of apical dendrites in somatosensory cortex
also revealed the loss of spines, but exclusively on dystrophic den-
drites, which were positive for both hyperphosphorylated tau as
well as intraneuronal Aβ (Bittner et al., 2010).
Transgenic mouse models, bearing PS1 mutations only, do not
exhibit plaque pathology, hence allow for the separate analysis
of the impact of PS1 mutations on dendritic spines independent
of amyloid pathology. The impact of additional overexpression
of either wildtype PS1 or the familial AD-PS1A246E (FAD–PS1)
mutation on dendritic spines was analyzed by another study (Jung
et al., 2011). Whereas apical tuft dendrites showed an increased
spine density for both types of PS1 overexpression, basal dendrites
only exhibited a higher spine density in the FAD–PS1 mice (Jung
et al., 2011). Interestingly, neither spine dynamics nor shape was
affected by the different PS1 overexpression, thus the authors sug-
gest a gain-of-function role for PS1 on dendritic spine plasticity
(Jung et al., 2011).
Besides themanifold observations of dendritic spine alterations
in AD mouse models, additional structural changes were charac-
terized by in vivo two-photon imaging, such as neuritic dystro-
phies, neurite curvature, and – breakage or dendritic shaft atrophy
(Tsai et al., 2004; Garcia-Alloza et al., 2006a). Axonal dystrophies,
seen in the immediate vicinity of plaques, also undergo constant
formation and elimination over the course of days to weeks (Tsai
et al., 2004). Interestingly, plaque pathology (i.e., Aβ deposition)
precedes neuritic pathology, as curved as well as dystrophic neu-
rites only occurred days to weeks after a plaque was newly formed
(Meyer-Luehmann et al., 2008). These results further support the
notion of amyloid plaques acting as a mediator of neurite and
spine pathology, which is most likely caused by the combination
of a high oligomeric Aβ concentration associated with plaques as
well as their space occupying nature (Kofﬁe et al., 2009) and is at
least partially due to calcineurin activation (Wu et al., 2010).
Knowing the kinetics of plaque pathology and the above-
mentioned associated structural changes allows for monitoring
the effects of treatment approaches aiming at the reduction of
amyloid burden. Immunotherapy has been proven to rapidly
clear plaques (Bacskai et al., 2001), reduce the number and size
of plaque-associated neuritic dystrophies (Brendza et al., 2005),
and to acutely increase spine formation in APP transgenic mice
(Spires-Jones et al., 2009a). Curved neurites around a plaque seem
to be positively affected by antioxidants (Garcia-Alloza et al.,
2006a, 2010), but not by γ-secretase inhibition (Garcia-Alloza
et al., 2009). Unfortunately, previous treatment studies have lim-
ited their analysis to a small subset of neuropathological features
seen in APP transgenic mice, thereby hindering the evaluation of
the efﬁcacy of the treatment approach per se. Future imaging stud-
ies should therefore aim atmonitoringmultiple neuropathological
events simultaneously.
IMAGING MICROGLIA IN APP TRANSGENIC MICE
Apart from the above-mentioned neuritic alterations associated
with amyloid plaque deposition, the immediate plaque vicinity is
characterized by an accumulation of glial cells. Resting microglia
are uniformly distributed throughout the brain. They are con-
sidered the surveillants of the brain, as their processes are highly
motile, constantly sampling the microenvironment, whereas the
soma itself remains stationary (Nimmerjahn et al., 2005). Once
microglia detect cues of a brain insult, they rapidly become acti-
vated in a multistaged process, allowing them to migrate to the
lesion site, release cytokines, and phagocytose material (Ketten-
mann et al., 2011). In AD, as well as in mouse models of AD,
microglial cells are associated with amyloid plaques (Itagaki et al.,
1989; Stalder et al., 1999). A recent in vivo imaging study demon-
strated that microglia migrate rapidly to newly formed plaques
(Meyer-Luehmann et al., 2008), a process which is enhanced by
immunotherapy targeting aggregated Aβ (Koenigsknecht-Talboo
et al., 2008). Their precise contribution to AD pathophysiology,
however, remains controversial, as they are ascribed both a pro-
tective and a detrimental role (Morgan et al., 2005; Johnston et al.,
2011).
Multiple studies have addressed the question, whether
microglia cells are of crucial relevance in the formation and growth
of amyloid plaques. There is some evidence from immunohis-
tochemical – and in vivo imaging experiments, suggesting that
microglia are able to phagocytose Aβ, thus restricting plaque
growth (Simard et al., 2006; Bolmont et al., 2008). However, this
is in contrast to an earlier electron microscopy study, in which
the authors failed to detect any phagocytosed Aβ within microglia
(Stalder et al., 2001) and a previous in vivo imaging study, where
microglia lacked intracellular dense core plaque material (labeled
with Methoxy-XO4), but were positive for protoﬁbrillar Aβ (Liu
et al., 2010). Surprisingly, microglial depletion was found to nei-
ther affect plaque count nor plaque size, thereby questioning a
causal involvement of microglia at least in the pathogenesis of
amyloid-β deposition (Grathwohl et al., 2009).
A number of in vivo studies have tried to unravel the inﬂu-
ence of microglial activation,mediated by the chemokine receptor
CX3CR1, on amyloid pathology, and associated neurotoxicity
(Cardona et al., 2006; Fuhrmann et al., 2010; Liu et al., 2010).
Notably, CX3CR1-deﬁcient APP transgenic mice showed gene
dose dependent reduction of amyloid deposition (Lee et al., 2010).
Disruption of neuron–microglia interaction via fractalkine signal-
ing seems to alter microglia activation and phagocytic capacity,
thereby resulting in an enhanced phagocytosis of protoﬁbrillar Aβ
(Lee et al., 2010; Liu et al., 2010).
In a separate in vivo imaging study, triple transgenic mice
(3xTg-AD; Oddo et al., 2003), crossbred to mice lacking the
CX3CR1 receptor, showed no neuron loss, indicating a crucial
role of the microglial chemokine receptor in mediating neu-
ronal apoptosis (Fuhrmann et al., 2010). Interestingly, at the age
of 4–6months, 3xTg-AD animals do neither exhibit neuroﬁbril-
lary tangle nor amyloid plaque pathology. This gives rise to the
question of what the causing agent inducing the expression of
fractalkine in subsequent apoptotic neurons is. One likely can-
didate is intracellular Aβ, as mice at the age analyzed do not
yet possess hyperphosphorylated tau proteins. But why are other
mouse models, which also exhibit intracellular Aβ, devoid of neu-
ronal apoptosis? And furthermore, it remains unsolved whether
microglia are causally involved in the apoptotic process or just
recruited to the site of insult. In other words can interference with
the CX3CR1 pathway prevent neuronal loss? Taken together, the
role of microglia cells in the course of AD pathology is far from
clear. Hopefully chronic two-photon imaging studies will help to
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resolve some of the open questions regarding the precise nature of
microglial involvement in AD pathology.
IMAGING tau PATHOLOGY
Whereas in vivo imaging of amyloid-β pathology has been feasible
for quite some time,monitoring the second pathological hallmark
of AD, namely neuroﬁbrillary tangles in vivo, was only accom-
plished recently (Spires-Jones et al., 2008). NFT are thought to
occur and spread downstream of abnormalities of Aβ during the
course of AD (Gotz et al., 2004; Oddo et al., 2004; Santacruz et al.,
2005; Tanzi, 2005; Sperling et al., 2011), but their correlation to the
cognitive decline is much better than that observed for amyloid-β
pathology, arguing for the importance of NFT in the degenera-
tive process (Grober et al., 1999; Giannakopoulos et al., 2003).
Aggregation of hyperphosphorylated tau protein into NFT has
been suggested to contribute to neuronal loss in tau transgenic
mice (Andorfer et al., 2005; Ramsden et al., 2005; Santacruz et al.,
2005). The timing of hyperphosphorylated tau protein aggrega-
tion into tangles and the question whether NFT directly lead to
neuronal cell death are fundamental issues that are ideally suited
for in vivo two-photon imaging techniques.
The rTg4510 transgenic mouse model, which reversibly
expresses human tauP301L, is characterized by the development
of NFT, neuronal loss, and memory impairment (Ramsden et al.,
2005; Santacruz et al., 2005; Spires et al., 2006). These mice start to
build up NFT at 2.5months of age. Spires-Jones and co-workers
repeatedly imaged rTg4510 mice to study the kinetics of NFT
formation as well as the causal relationship between NFT and
neuronal cell death. Surprisingly, they found that neuroﬁbril-
lary tangle formation, caspase activation, and even the disruption
of membrane integrity do not immediately induce neuronal cell
death (Spires-Jones et al., 2008; de Calignon et al., 2009). Instead,
neuroﬁbrillary tangle formation occurred within 1 day after cas-
pase activation, and the respective neurons remained healthy for
several days (de Calignon et al., 2010). The authors thus propose
that tangles may not be harmful or toxic per se (as opposed to
soluble hyperphosphorylated tau), but rather serve a protective
role against caspase activation and subsequent apoptosis. How-
ever, given the short follow-up period of 5 days, this hypothesis
needs further evaluation in order to rule out a slower process of
apoptosis. Moreover, it is unclear whether tangle bearing neu-
rons maintain their physiological functional properties, although
some evidence from in vitro experiments of rTg4510 cortical slice
cultures points to no apparent functional differences between
tangle – and non-tangle bearing neurons (Rocher et al., 2010).
These studies challenge our current view on the causal involve-
ment of one of the main neuropathological hallmarks of AD and
ultimately raise the question as to which neurons actually undergo
apoptosis in mouse models of tauopathies including the rTg4510
transgenic or the 3xTg-AD mice. Do these neurons represent rare
cases in which caspase activation does not result in the induction
of tangle formation?And if so,how can the occurrence of NFT cor-
relate with the degree of cognitive decline in AD? Can tangles be
regarded as proxy for the concentration of soluble tau? Besides all
these open questions the recent ﬁndings unraveled the temporal
sequence of events, clearly establishing caspase activation as the
initiating event in the process of tangle formation.
FUNCTIONAL IN VIVO IMAGING
IMAGING NEURONAL ACTIVITY
Given the structural changes accompanying thedepositionof amy-
loid plaques, it does not come as a surprise that neuronal function
is also altered in neuronal structures neighboring plaques. Con-
ventional electrophysiological methods to study the functional
properties of neurons either yield a low spatial resolution (record-
ings of groups of neurons, e.g., ﬁeld recordings or EEG) or only
allow for single cell analysis (e.g., patch clamp). One elegant way of
analyzing the spatio-temporal dynamics of cell populations, with
single cell resolution, is in vivo two-photon imaging using calcium
indicators. Calcium indicators take advantage of the fact that elec-
trical activity of an excitable cell is tightly coupled to changes
in intracellular calcium concentration (Tsien, 1981; Stosiek et al.,
2003). Two main classes of indicators are available: synthetic dyes
(e.g., OGB-1, Fluo-4, Rhod-2), which are applied by the bolus
loading technique (Stosiek et al., 2003; Garaschuk et al., 2006),
and genetically encoded calcium indicators (e.g., GCaMP, yellow
chameleon, troponin C-based indicators), which are delivered to
the brain by viral vectors or electroporation (Grewe and Helm-
chen, 2009). Genetically encoded calcium indicators allow for
chronic functional imaging. In addition to being a proxy of neu-
ronal activity, calcium plays an important role as intracellular
signaling molecule in a number of processes, such as synap-
tic plasticity (transmitter release, excitability) and development
(dendritic development, synaptogenesis, growth cone behavior;
Ryglewski et al., 2007).
Calcium homeostasis and signaling are known to be disrupted
in AD (Berridge, 2011). Hence, in vivo calcium imaging can be
employed to address both the detection of altered calcium con-
centrations under baseline (i.e., resting) conditions, as well as
changes in neuronal/glial activity. Two papers recently addressed
the relationship between amyloid plaques and either intracellular
calcium concentration or neuronal activity (Busche et al., 2008;
Kuchibhotla et al., 2008). Garaschuk and co-workers for the ﬁrst
time described aberrant neuronal activity in the immediate vicin-
ity of amyloid plaques in APP23xPS45 mice (Busche et al., 2008).
UsingOregonGreenBAPTA-1AM(OGB-1AM) as a calcium indi-
cator, they found signiﬁcantly more cells (50% in APP23xPS45
vs. 12% in WT) with extremely low or very high activity lev-
els in frontal cortex (layer II/III) of APP23xPS45 compared to
non-transgenic wildtype mice. When analyzing the spatial distri-
butionof these neurons, they observedhyperactive cells exclusively
within a 60μm radius from the next amyloid plaque. Silent cells
and such with regular ﬁring rates were distributed throughout the
cortex, with a relative increase of silent cells further away from
plaques. Pre-depositing mice on the other hand did not show
any abnormal neuronal activity patterns. In order to disentan-
gle the mechanism underlying the hyperactivity, the authors used
a pharmacological approach and increased or decreased GABAer-
gic inhibition. Hyperactive cells responded to both treatments, but
exhibited a lower relative frequency increase after application of a
GABAA receptor antagonist compared to silent or regularly ﬁring
cells. Hence, the authors suggest that impaired synaptic inhibition
underlies the observed hyperactivity (Busche et al., 2008).
A nicely complementing study more speciﬁcally investi-
gated calcium concentrations within dendrites and spines using
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the ratiometric genetically encoded calcium indicator yellow
chameleon (YC3.6; Kuchibhotla et al., 2008). A large proportion of
dendrites in the immediate vicinity of amyloid plaques exhibited
an overload of resting calcium concentration (Kuchibhotla et al.,
2008). As a consequence, a disruption of spino-dendritic com-
partmentalization, a feature thought to be necessary for proper
synaptic network integration (Augustine et al., 2003; Bloodgood
and Sabatini, 2007), was observed. Furthermore, the study pro-
vided a link between structural and functional alterations, since
more than half of the neurites with elevated calcium concentration
were beaded, i.e., dystrophic (Kuchibhotla et al., 2008).
Taken together, these studies pinpoint amyloid plaques asmedi-
ators of functional alterations observed inAD mouse models, both
on the cellular as well as on the subcellular level. Furthermore,
they link structural changes to altered function,which presumably
underlies the neuronal network dysfunction prominent in AD. To
date, no study has addressed chronic changes in neuronal activity.
Recently developed genetically encoded calcium indicators allow
for repeated functional imaging, thereby providing a valuable tool
to monitor the induction and progression of the above-mentioned
functional neuronal alterations.
IMAGING ASTROCYTIC ACTIVITY
Another cell type known to exhibit large calcium signals are
astrocytes. Astrocytes are involved in numerous physiological
processes, such as neurovascular coupling, provision of nutri-
ents to neurons, balance of extracellular ion concentration, and
the uptake and release of neurotransmitters (“tripartite synapse”;
Araque et al., 1999; Verkhratsky, 2010; Verkhratsky and Parpura,
2010). They also play a crucial role under pathological conditions,
such as stroke, epilepsy, traumatic brain injuries, multiple scle-
rosis, and neurodegeneration (Verkhratsky et al., 2010; Sidoryk-
Wegrzynowicz et al., 2011). Astrocytes are speciﬁcally implicated
in AD pathology as they are, along with microglia, recruited to
amyloid plaques (Itagaki et al., 1989; Nagele et al., 2004; Tuppo
and Arias, 2005). Reactive astrogliosis may be triggered by fac-
tors released by affected cells as well as amyloid-β deposits, and
results in an enhanced gap-junction coupling between cells (Pih-
laja et al., 2008; Peters et al., 2009). The particular role of astrocytes
is not yet fully understood. Whereas active glial cells might convey
detrimental effects on neurons by releasing cytokines, interleukins,
reactive oxygen species, or TNFα (Johnstone et al., 1999; Akiyama
et al., 2000; Koistinaho et al., 2002), astrocytes are also linked to the
clearance of plaques, as they can phagocytose deposited Aβ (Wyss-
Coray et al., 2003; Koistinaho et al., 2004; Pihlaja et al., 2008).
To investigate the functional response of astrocytes to amyloid
plaques in APPswe/PS1dE9 mice in vivo, Kuchibhotla et al. (2009)
co-injected the calcium indicator OGB-1AM and sulforhodamine
101(SR 101) in order to counterstain astrocytes (Nimmerjahn
et al., 2004). They observed a globally elevated resting calcium
concentration within the astrocytic network, independent of amy-
loid plaque proximity. Synchronous calcium transients were much
more frequent in APP/PS1 than in non-transgenic control mice,
and appeared in a coordinated fashion across long distances, but
were uncoupled from neuronal activity (Kuchibhotla et al., 2009).
Furthermore, the authors succeeded in detecting calcium waves
between astrocytes in vivo, exclusively inmice alreadybearing amy-
loid plaques. These waves seem to originate in the plaque vicinity
and travel radially over ∼200μm, thereby indicating a focal neu-
ropathological insult (Scemes and Giaume, 2006). In conjunction
with in vitro studies, these ﬁndings emphasize the active contribu-
tion of astrocytes to AD neuropathology (Rodriguez et al., 2009).
CONCLUSION
While great progress towards understanding themolecularmecha-
nisms and genetic pre-dispositions of ADhas been achievedwithin
the past two decades, therapeutic options that halt or reverse the
disease are still not available to date. Further research, unravel-
ing underlying cellular and molecular mechanisms, and validating
newly developed treatment approaches is thus needed. Performing
transcranial in vivo two-photon microscopy on transgenic mouse
models of AD has shed much light upon the kinetics and temporal
sequence of neuropathological AD hallmarks and their associated
structural and functional alterations in the living intact brain.
In vivo imaging data stress the relevance of amyloid plaques as
a focal source of neurotoxicity, as numerous pathological features,
such as the occurrence of dystrophic neurites, neurite breakage,
spine loss, clusters of hyperactive neurons as well as the initiation
of intracellular calcium waves among astrocytes, are tightly spa-
tially and temporally linked to plaque deposition. Furthermore,
recent studies challenge our current understanding of the toxic
nature of NFT by proposing a protective role for these intracellu-
lar aggregates. Future research will hopefully provide more insight
into the causality of the observed pathological features as well
as the efﬁcacy of newly developed treatment approaches by, e.g.,
combining and correlating longitudinal imaging approaches and
behavioral studies.
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